Paul Choi
Stock Analyst at Goldman Sachs
(3.41)
# 1,049
Out of 4,412 analysts
62
Total ratings
50%
Success rate
3.38%
Average return
Main Sectors:
24 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Maintains: Buy | $9 → $8 | $0.67 | +1,097.60% | 3 | Mar 6, 2024 | |
| ARVN Arvinas | Initiates: Buy | $70 | $32.37 | +116.25% | 1 | Feb 1, 2024 | |
| DVAX Dynavax Technologies | Initiates: Neutral | $20 | $11.21 | +78.41% | 1 | Feb 1, 2024 | |
| HCM HUTCHMED (China) | Maintains: Neutral | $15 → $17 | $18.16 | -6.39% | 5 | Nov 10, 2023 | |
| CYTK Cytokinetics | Initiates: Buy | $50 | $65.34 | -23.48% | 1 | Nov 9, 2023 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $9 → $10 | $9.18 | +8.93% | 5 | Nov 3, 2023 | |
| PTCT PTC Therapeutics | Maintains: Sell | $35 → $22 | $28.57 | -23.00% | 3 | Sep 18, 2023 | |
| URGN UroGen Pharma | Maintains: Neutral | $11 → $18 | $14.15 | +27.21% | 2 | Jul 31, 2023 | |
| KNSA Kiniksa Pharmaceuticals | Maintains: Buy | $22 → $32 | $17.88 | +78.97% | 1 | Jul 26, 2023 | |
| VIR Vir Biotechnology | Maintains: Buy | $51 → $28 | $8.23 | +240.22% | 6 | Jul 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Sell | $1.5 → $1 | $0.87 | +14.30% | 5 | Jul 20, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $29 → $50 | $24.88 | +100.96% | 4 | Jul 18, 2023 | |
| FHTX Foghorn Therapeutics | Maintains: Buy | $21 → $19 | $5.49 | +246.08% | 3 | Jun 29, 2023 | |
| FGEN FibroGen | Maintains: Sell | $16 → $2 | $1.04 | +92.31% | 7 | Jun 27, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $60 | $40.50 | +48.15% | 1 | Dec 14, 2022 | |
| ASND Ascendis Pharma | Initiates: Buy | $174 | $135.90 | +28.04% | 1 | Oct 20, 2022 | |
| PMVP PMV Pharmaceuticals | Maintains: Buy | $43 → $25 | $1.75 | +1,328.57% | 3 | May 24, 2022 | |
| ESPR Esperion Therapeutics | Maintains: Sell | $3.5 → $3 | $1.90 | +57.89% | 2 | May 24, 2022 | |
| ALLK Allakos | Maintains: Neutral | $10 → $4 | $1.02 | +292.16% | 3 | May 24, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Buy | n/a | $38.97 | - | 1 | Oct 6, 2021 | |
| RDUS Radius Health | Assumes: Buy | n/a | $17.90 | - | 1 | Mar 22, 2021 | |
| SWTX SpringWorks Therapeutics | Assumes: Buy | n/a | $45.53 | - | 1 | Mar 22, 2021 | |
| NBIX Neurocrine Biosciences | Downgrades: Neutral | n/a | $135.99 | - | 1 | Jun 29, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Neutral | n/a | $1.32 | - | 1 | Mar 30, 2020 |
Gossamer Bio
Mar 6, 2024
Maintains: Buy
Price Target: $9 → $8
Current: $0.67
Upside: +1,097.60%
Arvinas
Feb 1, 2024
Initiates: Buy
Price Target: $70
Current: $32.37
Upside: +116.25%
Dynavax Technologies
Feb 1, 2024
Initiates: Neutral
Price Target: $20
Current: $11.21
Upside: +78.41%
HUTCHMED (China)
Nov 10, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $18.16
Upside: -6.39%
Cytokinetics
Nov 9, 2023
Initiates: Buy
Price Target: $50
Current: $65.34
Upside: -23.48%
Phathom Pharmaceuticals
Nov 3, 2023
Maintains: Neutral
Price Target: $9 → $10
Current: $9.18
Upside: +8.93%
PTC Therapeutics
Sep 18, 2023
Maintains: Sell
Price Target: $35 → $22
Current: $28.57
Upside: -23.00%
UroGen Pharma
Jul 31, 2023
Maintains: Neutral
Price Target: $11 → $18
Current: $14.15
Upside: +27.21%
Kiniksa Pharmaceuticals
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $17.88
Upside: +78.97%
Vir Biotechnology
Jul 21, 2023
Maintains: Buy
Price Target: $51 → $28
Current: $8.23
Upside: +240.22%
Amarin Corporation
Jul 20, 2023
Maintains: Sell
Price Target: $1.5 → $1
Current: $0.87
Upside: +14.30%
BridgeBio Pharma
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $24.88
Upside: +100.96%
Foghorn Therapeutics
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.49
Upside: +246.08%
FibroGen
Jun 27, 2023
Maintains: Sell
Price Target: $16 → $2
Current: $1.04
Upside: +92.31%
Xenon Pharmaceuticals
Dec 14, 2022
Initiates: Buy
Price Target: $60
Current: $40.50
Upside: +48.15%
Ascendis Pharma
Oct 20, 2022
Initiates: Buy
Price Target: $174
Current: $135.90
Upside: +28.04%
PMV Pharmaceuticals
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.75
Upside: +1,328.57%
Esperion Therapeutics
May 24, 2022
Maintains: Sell
Price Target: $3.5 → $3
Current: $1.90
Upside: +57.89%
Allakos
May 24, 2022
Maintains: Neutral
Price Target: $10 → $4
Current: $1.02
Upside: +292.16%
Biohaven Pharmaceutical Holding Company
Oct 6, 2021
Maintains: Buy
Price Target: n/a
Current: $38.97
Upside: -
Radius Health
Mar 22, 2021
Assumes: Buy
Price Target: n/a
Current: $17.90
Upside: -
SpringWorks Therapeutics
Mar 22, 2021
Assumes: Buy
Price Target: n/a
Current: $45.53
Upside: -
Neurocrine Biosciences
Jun 29, 2020
Downgrades: Neutral
Price Target: n/a
Current: $135.99
Upside: -
Nektar Therapeutics
Mar 30, 2020
Upgrades: Neutral
Price Target: n/a
Current: $1.32
Upside: -